Lip, GYH;
Proietti, M;
Potpara, T;
Mansour, M;
Savelieva, I;
Tse, HF;
Goette, A;
Camm, AJ;
Blomstrom-Lundqvist, C;
Gupta, D;
et al.
Lip, GYH; Proietti, M; Potpara, T; Mansour, M; Savelieva, I; Tse, HF; Goette, A; Camm, AJ; Blomstrom-Lundqvist, C; Gupta, D; Boriani, G
(2023)
Atrial fibrillation and stroke prevention: 25 years of research at EP Europace journal.
Europace, 25 (9).
euad226.
ISSN 1532-2092
https://doi.org/10.1093/europace/euad226
SGUL Authors: Camm, Alan John
Abstract
Stroke prevention in patients with atrial fibrillation (AF) is one pillar of the management of this common arrhythmia. Substantial advances in the epidemiology and associated pathophysiology underlying AF-related stroke and thrombo-embolism are evident. Furthermore, the introduction of the non-vitamin K antagonist oral anticoagulants (also called direct oral anticoagulants) has clearly changed our approach to stroke prevention in AF, such that the default should be to offer oral anticoagulation for stroke prevention, unless the patient is at low risk. A strategy of early rhythm control is also beneficial in reducing strokes in selected patients with recent onset AF, when compared to rate control. Cardiovascular risk factor management, with optimization of comorbidities and attention to lifestyle factors, and the patient's psychological morbidity are also essential. Finally, in selected patients with absolute contraindications to long-term oral anticoagulation, left atrial appendage occlusion or exclusion may be considered. The aim of this state-of-the-art review article is to provide an overview of the current status of AF-related stroke and prevention strategies. A holistic or integrated care approach to AF management is recommended to minimize the risk of stroke in patients with AF, based on the evidence-based Atrial fibrillation Better Care (ABC) pathway, as follows: A: Avoid stroke with Anticoagulation; B: Better patient-centred, symptom-directed decisions on rate or rhythm control; C: Cardiovascular risk factor and comorbidity optimization, including lifestyle changes.
Item Type: |
Article
|
Additional Information: |
© The Author(s) 2023. Published by Oxford University Press on behalf of the European Society of Cardiology.
This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
Keywords: |
Ablation, Anticoagulation, Atrial fibrillation, Bleeding risk, Pacemaker, Rhythm control, Stroke prevention, Humans, Atrial Fibrillation, Stroke, Heart, Anticoagulants, Contraindications, Heart, Humans, Atrial Fibrillation, Anticoagulants, Stroke, Contraindications, Atrial fibrillation, Stroke prevention, Rhythm control, Ablation, Anticoagulation, Bleeding risk, Pacemaker, 1103 Clinical Sciences, Cardiovascular System & Hematology |
SGUL Research Institute / Research Centre: |
Academic Structure > Molecular and Clinical Sciences Research Institute (MCS) |
Journal or Publication Title: |
Europace |
ISSN: |
1532-2092 |
Language: |
eng |
Dates: |
Date | Event |
---|
2 August 2023 | Published | 25 August 2023 | Published Online | 17 July 2023 | Accepted |
|
Publisher License: |
Creative Commons: Attribution-Noncommercial 4.0 |
PubMed ID: |
37622590 |
Web of Science ID: |
WOS:001054221500001 |
|
Go to PubMed abstract |
URI: |
https://openaccess.sgul.ac.uk/id/eprint/115962 |
Publisher's version: |
https://doi.org/10.1093/europace/euad226 |
Statistics
Item downloaded times since 08 Jan 2024.
Actions (login required)
|
Edit Item |